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Abstract
Hemostatic complications are common in patients with ventricular assist devices.
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plex interactions between device surface, sheer stress, and blood flow. These factors
play among platelets, coagulation factors, and red cells. In this article, we review the
pathophysiology of hematologic complications (bleeding, acquired von Willebrand disthe clinical manifestations, and the management of each. We summarize the evidence
available for management of these entities and provide a pragmatic clinical review.
KEYWORDS

heart-assist devices, hemostasis, heparin‐induced thrombocytopenia, thrombosis, ventricular
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Essentials
• Hemostatic complications associated with ventricular assist devices (VADs) are common, and multiple manifestations can coexist in the
same patient.
• Pump thrombosis is a devastating complication that typically requires surgical management.
• Αcquired von Willebrand disease is an underdiagnosed manifestation associated with VADs that can complicate anticoagulant management.
• Maintaining a balance between bleeding and thrombosis risks is key to managing patients with VADs.

1 | INTRODUCTION

implanted in patients for end‐stage chronic heart failure as desti-

Over the past 2 decades, the use of ventricular assist devices (VADs)

a greater understanding and appreciation of the unique hemo-

has increased dramatically. The first VADs were used in acutely

static complications associated with these devices has developed.

ill patients as a bridge to transplant; more recently, left VADs are

In this review, we discuss the types of VADs currently in use and

nation therapy (ie, long‐term use). With the increased use of VADs,
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their indications. The pathophysiology and clinical manifestations

end‐stage HF awaiting transplant or those who are transplant

of coagulation defects seen in patients with VADs will be dis-

ineligible.10‒12

cussed, followed by management strategies of patients with these
complications.

The HeartMate 3 centrifugal continuous‐flow device is the
most recent VAD engineered to improve hemocompatibility and
reduce shear stress. It was compared with the HeartMate II in

2 | VENTRICULAR ASSIST DEVICES

the MOMENTUM3 (Multicenter Study of MagLev Technology in
Patients Undergoing Mechanical Circulatory Support Therapy With
HeartMate 3) trial, and showed superiority over the HeartMate II in

The burden of chronic heart failure (HF) is significant, with >870 000

the composite end point of disabling stroke and reoperation rate for

new cases diagnosed in the United States per year and a lifetime

pump thrombosis at 6 months after implantation, with an event‐free

risk of developing HF of 1 in 5 for men and women after the age of

survival at 6 months of 86.2% in the centrifugal‐flow pump group and

40.1 Despite advances in our understanding of this syndrome, mortality remains high, with a 50% mortality rate 5 years after diagnosis,
which is higher than several common malignancies. 2‒4 Moreover,

76.8% in the axial‐flow pump group. There was no difference in death
or disabling stroke between the groups, but reoperation for pump
malfunction was less frequent in the centrifugal‐flow pump group

the number of individuals who progress to end‐stage HF remains

than in the axial‐flow pump group.13 This device is approved for use in

large, with few durable long‐term treatment strategies. Great strides

the European Union and was approved by the FDA in October 2018

have been made in medical and device therapy for HF; however, the

for use as short‐term and long‐term therapy for patients with ad-

prevalence of HF continues to rise, with estimates of a 46% increase

vanced refractory HF. The ENDURANCE (The HeartWare Ventricular

by 2030 with total costs estimated at almost $70 billion.1 Beyond
medical therapy, heart transplant remains the best therapy for end‐
stage HF with actuarial survival approaching 14 years.5 However,

Assist System as Destination Therapy of Advanced Heart Failure) trial
similarly assessed the safety and effectiveness of the centrifugal‐flow
left VAD—HeartWare HVAD (Medtronic, Dublin, Ireland)—relative to

few individuals are candidates for this treatment, and the demand

a control, axial‐flow left VAD in patients with advanced heart failure.

far exceeds the supply.

The primary end point of survival at 2 years free from disabling stroke

Mechanical circulatory support has been in evolution since the

or device removal for malfunction or failure in the intention‐to‐treat

National Institutes of Health first started the artificial heart program

population showed that the HeartWare centrifugal‐flow device was

in the 1960s. VADs are a manifestation of the program, serving now

noninferior to the control device.14

as destination therapy—treatment that supports the existing heart,

From these trials, it was clear that VADs are associated with signif-

not just until a heart transplant but also for the remainder of the

icant morbidity and mortality; morbidities include bleeding, infection,

patient's life. VADs have dramatically improved patients’ overall

pump thrombosis, and stroke. An analysis of US registry data of cu-

survival and quality of life. In addition to technical improvements in

mulative event rates in 8644 patients found that approximately 29%

device design, there has been a shift in patient selection from criti-

experienced bleeding events and 17% experienced neurologic com-

cally ill patients in shock to patients with advanced class III‐IV HF.6

plications (stroke and hemorrhage).15 Therefore, comorbid conditions

Since 2005, data from >15 000 patients have been entered into the

are important in candidate selection, and prior clotting disorders or

Interagency Registry for Mechanically Assisted Circulatory Support

bleeding diatheses are important considerations. Inability to tolerate

(INTERMACS).6 Outcomes are generally good, with enhanced survival (1‐year survival of 80%) and improved function and quality of
life.7
The first generation of devices used pulsatile technology with
integrated valve regulated flow. The first randomized trial, the

anticoagulation due to prior bleeding events on oral anticoagulants
remains a contraindication to VAD support. Additional comorbidities
such as renal and hepatic dysfunction, prior chest surgery, peripheral
arterial disease, and diabetes mellitus are important considerations
for optimal candidate selection and timing of VAD implant.

REMATCH (Randomized Evaluation of Mechanical Assistance for
the Treatment of Congestive Heart Failure) trial, demonstrated
a survival advantage of the pulsatile VAD over optimal medical
treatment. 8 Second‐ and third‐generation devices have addressed
device durability issues by removing valve‐regulated flow and mov-

3 | PATHOPHYSIOLOGY OF
HEMATOLOGIC COMPLICATIONS

ing to axial and centrifugal technology using blood as the bearing

The placement of a VAD can lead to a variety of hematologic com-

fluid. As such, the REMATCH II trial was conducted 10 years after

plications. The etiology of these complications is due to both the

REMATCH using the axial continuous‐flow HeartMate II (Thoratec

presence of a large foreign body (nonendothelial surface) and in-

Corp., Pleasanton, CA); it showed improved overall survival and

creased shear forces acting on flowing blood and its cellular compo-

reduction in adverse events compared to the pulsatile HeartMate

nents. Conceptually, there is a “VAD triad” analogous to Virchow's

XVE.9 The US Food and Drug Administration (FDA) subsequently

triad consisting of the interactions of (1) artificial surface, (2) blood

approved the HeartMate II device as destination therapy. It re-

alterations, and (3) the effects of abnormal flows (Figure 1). The

sulted in improved morbidity and mortality compared to first‐gen-

major blood components that are affected by the presence of a

eration devices, providing a more stable platform for patients with

VAD are coagulation factors, platelets, and erythrocytes.

|
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The presence of a nonendothelial surface can also be a source

Artificial surface

of platelet dysfunction. In one study, 69% of patients with VADs
had impaired ristocetin‐induced platelet aggregation and decreased
activity of plasma VWF, presumably due to lack of high‐molecular‐
weight VWF multimers. 24 Finally, the vast majority of VAD patients
VAD triad

are on antiplatelet agents, and those agents will augment platelet

Acquired VWD
Hemolysis
Thrombosis
Bleeding

dysfunction. 25 Clinically, the platelet function assays are abnormal in

Shear force
FIGURE 1

all patients, likely reflecting both platelet dysfunction and acquired
von Willebrand disease (aVWD). 26,27
Blood changes

VAD Triad

3.3 | Erythrocytes
Erythrocytes do not tolerate the high shear forces found in VADs
and can be disrupted. The magnitude of the shear force needed to
disrupt erythrocytes is 15 times higher than that required to unfold

3.1 | Coagulation factors

von Willebrand protein and 3 times higher than that required to ac-

When placed, the VAD presents a large area of a nonendothelial sur-

tivate platelets, so only a limited amount of VAD blood flow leads to

face to flowing blood. Plasma protein absorption by the surface is the

red cell destruction. 20 Routinely, with VAD placement there is an in-

16

These proteins include fibrinogen and contact

crease in hemolysis due to presence of focal areas of very high shear.

pathway proteins (factor XII, kallikrein and high‐molecular‐weight

However, this hemolysis is markedly accentuated with the formation

kininogen). Fibrinogen can offer binding sites for platelets, leading

of pump thrombi. 28 Presence of thrombin in the blood flow leads to

to the formation of platelet aggregates. The binding of the contact

local areas of very high shear, with resultant erythrocyte destruction

system proteins to the surface leads to activation of coagulation by

and clinically evident hemolysis.

first thing to occur.

generating factor IXa, which can then lead to thrombin generation.17
Studies have shown that with VAD placement there is depletion of
contact pathway proteins over the first 2 weeks, suggesting activation with resultant protein depletion.18

4 | CLINICAL HEMATOLOGIC
MANIFESTATIONS
4.1 | Acquired von Willebrand disease

3.2 | Platelets

The high shear stress associated with VADs leads to aVWD. Von

Platelets become activated both by interactions with the nonen-

Willebrand protein is synthesized as a dimer that then polymerizes

dothelial surface and by the high shear forces. The nonendothelial

to form ultra‐large multimers over 20 000 kD in size. When released

surface introduced can activate platelets directly, independently of

from endothelial cells, these ultra‐large multimers are large enough

fibrinogen or contact system proteins. In an in vitro study, 15 min-

to allow spontaneous binding and aggregation of platelets. As spon-

utes after blood was exposed to a surface, 5 to 16 platelets per

taneous platelet aggregation is undesirable in normal circumstances,

1000 μm were deposited—with this number increasing by 40% to

von Willebrand protein undergoes cleavage by ADAMTS‐13, result-

The presence of a rapidly rotat-

ing in formation of high‐molecular‐weight (HMW) multimers. The

ing pump is another surface reaction that can lead to very high shear

multimers are <20 000 kD in size but are the most effective in pro-

forces, much more than those found in normal circulation; this can

moting hemostasis.

19

50% with the applied shear force.

lead to alterations in von Willebrand protein, platelets, and erythro-

Von Willebrand protein usually circulates in a folded‐up configu-

In the above‐mentioned in vitro model, levels of platelet fac-

ration, but under shear stress it can extend into long strings. 29 This

tor 4 (PF4)—a marker of platelet activation—were increased within

unfolding exposes the von Willebrand A2 domain, which is a site for

120 minutes. 21 High shear unfolds von Willebrand protein, exposing

ADAMTS‐13 cleavage, leading to loss of the most hemostatically

platelet‐binding sites. Platelets bind and become activated, recruit-

effective HMW multimers. In addition, high levels of shear forces

ing more platelets to bind to von Willebrand proteins, resulting in the

can lead to physical breakdown of HMW multimers, which further

cytes.

20

formation of platelet thrombi.

22

One would hypothesize that activa-

adds to the aVWD.30 The onset of aVWD after VAD placement is

tion of platelets can lead to platelet deposition in the inner linings of

rapid, often occurring immediately after surgery.31,32 In an in vitro

the thrombus. However, a histopathologic analysis of thrombi from

model, the onset of aVWD was within 2 hours of starting blood flow

the HeartMate II VAD showed that the inner rings of the throm-

through the device, demonstrating the rapidity of protein degrada-

bus were rich in fibrin and von Willebrand factor (VWF). Platelets

tion. 21 The aVWD appears to last as long as the VAD is in place—

were found in the outer rings, suggesting that they may have a role

even up to 80 months. The resolution of aVWD is also rapid after

in thrombus growth as well. 23

VAD removal—often within 1 week.33
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On laboratory testing, the levels of von Willebrand protein are

administration of hemoglobin preparations to healthy human vol-

markedly elevated, but ratio of von Willebrand activity to protein are

unteers, resulting in abdominal pain, esophageal spasms, and

markedly lower, <0.7, reflecting the loss of the HMW multimers.34

dysphagia.42

Multimer analysis demonstrates that the levels of the HMW frac-

The seventh INTERMACS annual report showed that patients

tions are decreased by 30%, with a concomitant rise in the medium‐

who required a pump exchange had a worse survival compared to

and low‐molecular‐weight fractions. 26 Studies reveal that decreased

patients who did not require a pump exchange.6 However, this likely

or absent HMW multimers are very common, occurring in virtually

reflects poor outcomes once refractory hemolysis develops regard-

all patients with a VAD.33 However, the level of VWF activity of pro-

less of whether patients undergo pump exchange. In another study,

tein is not the only explanation for clinical bleeding seen in patients

patients treated with medical therapy intensification had worse out-

with VADs.

35

In one prospective study, 27% of patients with loss of

HMW multimers had bleeding complications. 27

comes than patients who underwent pump exchange (1‐year freedom from stroke or death of 49.5% and 87.5% in the medical and
surgical cohorts, respectively; P = 0.027.43

4.2 | Hemolysis
Hemolysis is a common phenomenon seen after implantation of a

4.3 | Thrombosis

VAD. In clinical practice, hemolysis can be an early marker of throm-

Despite many efforts put in place to make the VAD surface less

bosis, and routine monitoring for changes in plasma free hemoglobin

thrombogenic as well as the use of aggressive anticoagulation tech-

and/or lactate dehydrogenase (LDH) help to diagnose potential

niques, thrombotic complications remain the most feared VAD‐re-

thrombus development. Patients may have asymptomatic changes

lated complications with rates of 7% to 16% per year.44,45

in these serum markers, and a careful assessment of pump parameters and markers of ventricular unloading through noninvasive or
invasive means is important in deciding either to increase anticoagu-

4.3.1 | Stroke

lation, to administer thrombolytics, or to proceed to pump exchange.

Strokes occur with an incidence ranging from 7% to 10% per year

One particular form of mechanical circulatory support (MCS) associ-

according to one meta‐analysis.46 Studies consistently show that

ated with hemolysis is the Impella device, which is increasingly used

about 50% of strokes in this setting are embolic and 50% are hem-

in cardiogenic shock. The rate of hemolysis is approximately 60% in

orrhagic.47,48 The etiology of embolic strokes is assumed to be for-

patients who require long‐term (>24 hours) support.

36

mation of thrombi in the pump, which are then the source of the

Free hemoglobin is routinely used to assess erythrocyte de-

emboli, as they have direct access to the arterial outflow. However,

struction. False‐positive results can be seen when hemolysis occurs

it is important to recognize that patients with HF may have atrial

during blood sampling and in high bilirubin states, such as in hepatic

fibrillation and prior left ventricular mural thrombi, both of which

dysfunction from right ventricular heart failure, drugs, or sinusoidal

may be sources of thrombus formation. Hemorrhagic strokes may

endothelial dysfunction.37 Haptoglobin, a protein synthesized by

be primary brain bleeds or hemorrhagic transformation of em-

the liver, binds free hemoglobin in states of hemolysis and is usually

bolic strokes. Strokes are an adverse prognostic indicator, with a

depleted. However, reduced synthesis due to liver impairment can

case fatality rate of 13% and double the risk of death over the long

result in low levels of haptoglobin without hemolysis. An increase in

term.45,49 International normalized ratio (INR) control appears to be

LDH of >2.5 times the upper limit of normal can be indicative of early

important, as strokes are increased with INR <1.5 to 2.0, and hemor-

device thrombosis.11

rhagic strokes increase with INR >3.0.50

Free hemoglobin is normally filtered through the glomerulus and
actively reabsorbed in proximal tubule cells, where it is catabolized
with release of iron in the form of hemosiderin. When the reabsorp-

4.3.2 | Pump thrombosis

tion capacity of the kidney is exceeded, hemoglobinuria occurs.38

The other devastating thrombotic complication of VAD placement is

This can lead to acute renal failure during severe episodes of in-

pump thrombosis. Rates vary in the literature but range from 5.5% to

travascular hemolysis. Furthermore, chronic intravascular hemoly-

12%.51 Diagnosis of early thrombosis can be subtle, but 4 early signs

sis can lead to hemosiderin deposition in the proximal tubule and

are pump power elevation, a rise in LDH, evidence of hemolysis, or

Fanconi syndrome.39

new heart failure symptoms.52 A rise in LDH is a sensitive and early

Other clinical manifestations of intravascular hemolysis are re-

sign of pump thrombosis.53 Thrombi in the pump disrupt blood flow,

lated to local and systemic nitric oxide deficiency, resulting in endo-

causing an increase in shear forces and red cell destruction, which

thelial dysfunction. In animal models, nitric oxide has been shown

leads to a marked increase in LDH levels—often >1000 μ/L.51,54,55

to inhibit platelet aggregation and adhesion by increasing cyclic

Pump findings include increased power need or the finding that in-

guanine monophosphate levels.

40

In deficiency states, such as ni-

creasing power to the pump does not increase blood flow.54

tric oxide scavenging by hemoglobin, platelet aggregation increases,

Imaging with echocardiography or computed tomography can

as shown in studies of healthy volunteers.41 Nitric oxide also has

show either signs of thrombosis or changes in blood flow sugges-

a role in smooth‐muscle regulation.38 This was demonstrated by

tive of obstruction to flow that may be consistent with thrombosis in

|
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the pump. The pump ramp test looks to evaluate whether increasing

fondaparinux.63,64 For patients with renal insufficiency, argatroban

pump speed leads to decreased left ventricular volume or unloading

is the preferred choice. Clearance of argatroban is decreased in he-

of the ventricle. In a normal‐functioning VAD, the increased speed

patic disease, and the dose is typically decreased as well. Given its

would lead to “draining” of the ventricle, but if the flow is blocked,

long half‐life, renal clearance, and lack of validated methods for mon-

this decrease in ventricular size is blunted. Falling blood pressure and

itoring, fondaparinux is not routinely used in patients with MCS. Our

cardiogenic shock are late signs.

preferred choice is therefore bivalirudin unless a patient has severe

The rate of pump thrombosis for the patients with a HeartMate

renal insufficiency.

II VAD was noted to be increased in many centers in 2013.11 The
etiology for this is not known, but speculation ranges from subtle
changes in the pump design and preparation to less intense antico-

4.5 | Bleeding

agulation or to no heparin bridging after pump placement. An anal-

Bleeding can occur in up to 80% of patients with VADs, with a

ysis of this device in the INTERMACS registry found an increase in

meta‐analysis reporting an overall rate of 30% (10% of which are

pump exchange due to thrombosis from 2009 to 2012. 56 Indeed,

fatal).45 There are several patterns of bleeding. There is an early

pump design may also play a role in prevention. The HeartMate

increased incidence of bleeding with or after surgery requiring

3, a fully magnetically levitated centrifugal continuous‐flow pump

reoperation in 14% to 30% of patients. 65‒67 Factors that put pa-

with a change in speed every 2 seconds as a means to wash the

tients at risk for surgical bleeding include anticoagulation before

rotor, showed lower rates of pump thrombosis compared to the

surgery and renal and/or liver dysfunction due to heart failure.

13

HeartMate II.

Other risk factors for surgical bleeding are older age and cardiogenic shock. 65,68

4.4 | Heparin‐induced thrombocytopenia

The need for long‐term combination antiplatelet and antithrombotic therapy is a risk factor for bleeding. In addition, aVWD

The combination of heparin exposure and increased platelet activa-

and platelet dysfunction are also risk factors for bleeding. Finally,

tion places patients with VADs at risk for heparin‐induced thrombo-

changes in blood flow due to the VAD, especially continuous‐flow

cytopenia (HIT). HIT is a platelet activation syndrome mediated by

models, may lead to anatomic causes of bleeding. In the late post-

antibodies to heparin‐PF4 protein complexes that activate platelets

operative period, bleeding is usually from the gastrointestinal (GI)

and lead to thrombocytopenia and thrombosis. One difficulty in as-

tract or intracranial. The most serious site of bleeding is intracranial

sessing both patients and the literature on HIT incidence is the pres-

hemorrhage, with rates of 1% to 9% per year being reported.69 In a

ence of frequent false‐positive anti‐PF4 antibodies, evaluated by

pediatric series, the rate was 17%, with most patients dying of the

PF4 ELISA, in this setting as with any cardiac surgery population.55

intracranial bleed.70

Studies do show high rates of PF4 antibody formation in the 50%

The most common site of bleeding is the GI tract, with up to 5%

range, but the rate of finding platelet‐activating PF4 antibodies is

to 40% suffering this complication.71‒74 The site of bleeding can

10%, which is higher than in cardiac surgery or other high‐risk set-

be anywhere in the GI tract and is often a challenge to diagnose,

tings.57‒60 The presence of platelet‐activating PF4 antibodies does

as it may be related to diffuse angiodysplasia. Studies showed an

markedly increase the risk of thrombosis.

8.7% to 38% rate of ulcers and gastritis, presumably due to both

The most sensitive sign of HIT is a ≥50% fall in the platelet
count.

59

antiplatelet agents and stress.72,75 Arteriovenous malformations

In assessing the VAD patient at risk for HIT, one needs to

are a particular source of bleeding, especially in patients with

keep other causes of thrombocytopenia in mind, such as recent sur-

continuous‐flow pumps.72 With the advent of continuous‐flow

gery or infections. The 4Ts score is a pretests clinical scoring system

devices, the risk of GI bleeding was noted to increase—in some

that takes into account the degree of thrombocytopenia, timing of

studies >10‐fold over pulsatile flow devices.71 In these patients,

platelet count fall, other causes of thrombocytopenia, and throm-

the site of bleeding was found to be arteriovenous malformation,

bosis, and has been shown to have a high negative predictive value

with a rate of 20% to 60% being reported.76 Given the associa-

(ie, low‐probability 4Ts score essentially excludes HIT) in a system-

tion of continuous‐flow pumps and arteriovenous malformation, it

atic review and meta‐analysis.61 Furthermore, one study has shown

has been hypothesized that the lack of pulse pressure is a key risk

that combining 4Ts clinical score with the PF4 ELISA test increases

factor for the development of abnormal vasculature. Supporting

sensitivity and specificity.62 In patients with thrombocytopenia and

this idea is the increased risk of arteriovenous malformations seen

a high 4Ts score, especially with new thrombosis, blood should be

in other disease states marked by lack of pulse pressure such as

drawn for PF4 ELISA testing. If the ELISA test is positive, patients

aortic stenosis.77 Theories on etiologies for arteriovenous mal-

need to be changed to an alternative anticoagulation. Given the high

formations range from an increased sympathetic tone leading to

false‐positive rate, anti‐PF4 antibodies need to be confirmed with

smooth‐muscle relaxation and vessel dilation to hypoperfusion

heparin‐induced platelet activation testing (serotonin release assay),

resulting in local hypoxia and vascular dilation.73,75 Other postu-

which is specific for HIT.

61

The first step in treatment of HIT is to avoid heparin.
Alternatives for anticoagulation include argatroban, bivalirudin, or

lated mechanisms include the impact VWF may have on vascular integrity, including the possibility that VWF fragments may be
proangiogenic (Table 1).78
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TA B L E 1

Hematologic manifestations and their management
Signs

Treatment

Long‐term

Pump thrombosis

Increase LDH or plasma free hemoglobin, hemolysis, new or worsening
heart failure, failed pump ramp test

Heparin Eptifibatide
Thrombolytics (intravenous or
intraventricular)
Surgery preferred (pump replacement)

Increase INR range 2.5‐3.5
Increase aspirin dose to 325 mg/daily

Heparin‐induced
thrombocytopenia

Thrombosis, thrombocytopenia without
alternative explanation (drug‐induced,
sepsis)

Argatroban
Bivalirudin

Avoid heparin products

Bleeding

Depends on site of bleed and severity

Warfarin: prothrombin complex
concentrate
Antiplatelet agents
• Aspirin: 1 plateletpheresis unit
• Other agents: 2 plateletpheresis units

Reduce INR goal to 1.5‐2.0 (if moderate bleed), or halt (if severe bleed)
Risk/benefit discussion

INR, international normalized ratio; LDH, lactate dehydrogenase.

22% in a retrospective control group, but these results need to be

5 | MANAGEMENT STRATEGIES

confirmed in a randomized clinical trial.83

5.1 | Bleeding
Life‐threatening major hemorrhage is managed with immediate reversal of anticoagulation using prothrombin complex concentrate
79

for warfarin

5.2 | Anticoagulation
Antithrombotic therapy with both anticoagulation and antiplatelet

and platelet transfusions to reverse the antiplatelet

agents is crucial in preventing thrombotic complications in VAD pa-

effect. The role of von Willebrand replacement is controversial given

tients. It was once standard that patients after VAD placement be

that any infused factor is likely to be rapidly degraded.15 It has been

treated with heparin until warfarin achieves a therapeutic INR. Now

proposed that reducing pump speed may help, as this may lessen

it is not uncommon to find heparin being held in this period to de-

shear forces and degradation of VWF. However, even with reduced

crease early postoperative bleeding rates.84‒87 However, this lack of

pump speed, the shear forces generated are still an order of magni-

heparin has led to recent concern of an association with increased

tude greater than physiologic levels and von Willebrand degradation

risk of pump thrombosis. It may be prudent to limit holding heparin

still occurs. For patients with GI bleeding, where most studies show

to patients at high risk of bleeding, such as those with previous GI

the majority of the bleeding lesions are in the upper tract, esophago-

bleeding or other risk factors for hemorrhage.84

gastroduodenoscopy (EGD) is the first diagnostic approach. If EGD

Given the role of platelet activation by surfaces and shear, aspirin

is negative, a pill endoscopy is an option to image the small bowel,

is started when surgical bleeding stops. There is no consensus on dos-

which is often the site of arteriovenous malformations.66,75 For pa-

ing, with recommendations ranging from 81 to 325 mg depending on

tients with frankly bloody stools, colonoscopy is the first choice for

centers.87 One center has reported decreased stroke risk with 325‐

evaluation.

mg dosing, but other studies show increased bleeding.65 Conversely,

Mild to moderate bleeding requires an individualized assessment

a small study eliminated the use of aspirin and used warfarin with an

to identify the best approach for management. Epistaxis or mild GI

INR of 2 to 2.5 with low thrombosis and bleeding rates. This provoca-

bleeding can be managed by holding aspirin. Another approach is

tive finding will need to be confirmed by larger studies.88

to lower the INR goal; however, it has been shown that lessening of

Warfarin is started with varied INR goals among centers as well

anticoagulation may lead to thrombosis. Having a GI bleed is also a

as consideration of patient risk factors for either bleeding or throm-

7.4‐fold risk factor for stroke, perhaps due to the need to decrease

bosis.45 Most INR goals are in the 2 to 3 range, but many centers

or halt anticoagulation.72

using HeartMate II will drop this to 1.5 to 2.5 based on data show-

Longer‐term management of bleeding patients is less settled, as

ing less bleeding with no increase in thrombosis with INRs in this

patients often rebleed after the first event.72 Reduction of anticoag-

range.84,89 Studies show that with HeartMate II patients, the highest

ulation should be considered only for patients with recurrent severe

rate of thrombosis was with INRs <1.5, but the rate was still high

bleeding. However, even off anticoagulation, the rate of rebleeding

with INRs of 1.5 to 2.0. Bleeding increases slightly with INRs >2.5 to

approaches 40%.80 There are anecdotes about the use of octreotide

3.0 but increases substantially with INRs >3.5.49 One challenge with

to control bleeding from arteriovenous malformations, but results

warfarin is that, due to illness and polypharmacy, these patients have

are contradictory, and again this should be reserved for patients for

may have unstable INRs. The time in therapeutic range for VAD pa-

81,82

There are

tients is only 30% to 50%.65 This time in range is considerably lower

preliminary promising data for omega‐3 fatty acids, where the use

than that reported in atrial fibrillation patients, and this instability of

of 4 g daily resulted in lower rates of GI bleeding (3%) compared to

anticoagulation may add to both bleeding and thrombosis risk.

whom there are no other options to control bleeding.
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Traditionally, heparin is monitored by the activated partial thromboplastin time (APTT). However, this test can be affected by warfarin,
high factor VIII due to underlying inflammation, and hemolysis. Recent
studies have shown that the APTT underestimates heparin requirements for VAD patients when compared to heparin levels measured
by anti‐Xa activity.90 One of the factors responsible for this discrepancy is residual warfarin effect. It has been shown that for every 1.0‐
unit rise in INR >1, the APTT increases by 16 seconds, which can lead
to falsely high APTTs.91 Elevations of LDH >1000 also interfere with
the APTT assay. For patients who are taking or have recently taken
warfarin and for those with high LDHs, using heparin levels via the
anti‐Xa assay may result in more accurate heparin dosing and does not
lead to an increased risk of bleeding despite supratherapeutic APTTs.
The direct oral anticoagulants (DOACs) have been shown in the
setting of venous thromboembolism and atrial fibrillation to be just as
effective as warfarin with lesser rates of bleeding, including intracranial
hemorrhage and fatal bleeding. Given the lack of need for monitoring
as well as no food and minimal drug interaction, the DOACs are attractive for the replacement of warfarin in VAD patients. A small study
of 7 patients using dabigatran showed no excess rate of bleeding or
thrombosis.92 However, a single‐center, randomized trial of dabigatran
vs. warfarin was terminated early due to increased thromboembolic
events associated with dabigatran.93 Furthermore, given the negative
experience with dabigatran use in mechanical heart valves, routine use
cannot be recommended until ongoing clinical trials are completed.
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6 | PERIOPERATIVE MANAGEMENT FOR
NONCARDIAC SURGERY
As discussed previously, all patients with a left VAD will likely be
maintained on anticoagulation. In patients undergoing noncardiac
surgery, appropriate anticoagulation bridging should be undertaken.
Warfarin should be discontinued 2 to 5 days preoperatively and a
heparin infusion initiated until the morning of the planned procedure.96,97 For patients with a history of HIT, both argatroban and
bivalirudin are recommended for bridging. In some cases, patients
with an increased risk of bleeding due to platelet dysfunction and
aVWD may be safely taken to surgery without bridging if there is
concern for hemorrhage intra‐ or postoperatively.98
In the postoperative setting, anticoagulation should be resumed when the risk of postoperative bleeding is deemed acceptable.99 It is generally recommended that heparin be used in
this setting if there are no contraindications, but some case series have suggested that warfarin may be resumed without the
need for heparin. 85 Timing of resumption of antiplatelet therapy
is variable, but most published experiences suggest that aspirin
can be resumed 1 week postoperatively.100 The management of
bleeding in the postoperative period depends on the cause and
source of bleed. Surgical causes may need operative correction
and management. However, bleeding unrelated to the operation remains common (eg, GI bleeding) and must be monitored
postoperatively.101

5.3 | Pump exchange
Treatment of pump thrombosis is primarily surgical, involving
exchange of the pump or urgent cardiac transplant when feasible. While the patient is being evaluated, initial medical therapy
consisting of heparin is started, but this alone is considered insufficient to treat pump thrombosis.15,51,54 Some groups have tried
adding glycoprotein IIb/IIIa inhibitors, usually eptifibatide, for 24
to 48 hours, but this can be complicated by bleeding and stroke.
A large study using eptifabatide 0.1 to 2.0 μg/kg/min with no
bolus showed only a 17% success rate and a mortality rate of 41%
with a 63% rate of bleeding.94 Thrombolytics have also been tried
with a variety of dosing protocols, ranging from a 100‐mg bolus
of tissue‐type plasminogen activator (t‐PA) to an intraventricular
infusion of 1 mg/min, which can limit the total amount of thrombolytics infused. 54,95 A novel approach uses a low‐dose infusion of a
bolus of 3 mg and then a 5‐ to 6‐hour infusion of t‐PA at 3 mg/h.

54

However, the results of medical therapy are poor, with studies
showing only 23% to 50% success and high rates of complications:

7 | SUMMARY
VADs remain an important modality in the treatment of advanced
HF for those who cannot wait or are not candidates for heart transplantation. The balance of bleeding and thrombosis is complex, and
a multitude of patient and device characteristics can shift this balance. Careful assessment of bleeding and thrombotic risks should
occur prior to VAD implant. The perioperative phase is a complex
time that often results in activation of blood components and may
set the stage for future bleeding and/or thrombotic events, which
carry increased risks of morbidity and mortality.
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Data for surgical replacement are better, with only 0% to 6.5%
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early mortality, making this the therapy of choice.
The key to prevention of pump thrombosis is adequate anticoagulation. INRs must be monitored frequently to keep patients in the
therapeutic range. For patients with a history of pump thrombosis, it
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